Contineum director receives 19,000 stock options
Contineum Therapeutics director Todd R. Brady received a grant of stock options for 19,000 shares of Class A Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Contineum Therapeutics director Todd R. Brady received a grant of stock options for 19,000 shares of Class A Common Stock. The options have a $14.19 exercise price, were granted under the 2024 Equity Incentive Plan, and vest in full on June 26, 2027 or at the next annual stockholder meeting.
Insider Trade Summary
Grant/Award: 19,000 shares
Grant/Award
1 txn
Insider
Brady Todd R.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 19,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 19,000 contracts (Direct)
Footnotes (1)
- F1. Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.
Key Figures
Option grant size: 19,000 shares
Exercise price: $14.19 per share
Post-grant derivative holdings: 19,000 options
+1 more
4 metrics
Option grant size
19,000 shares
Stock Option (right to buy) for Class A Common Stock
Exercise price
$14.19 per share
Conversion/exercise price of granted stock options
Post-grant derivative holdings
19,000 options
Total stock options following transaction
Option expiration
June 25, 2036
Expiration date of director stock options
Key Terms
Stock Option (right to buy), 2024 Equity Incentive Plan, Non-Employee Director Compensation Program, Class A Common Stock, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
2024 Equity Incentive Plan financial
"Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan")"
Non-Employee Director Compensation Program financial
"pursuant to the Issuer's Non-Employee Director Compensation Program, as amended"
Class A Common Stock financial
"a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
vest in full financial
"Option will vest in full on the earlier of (i) June 26, 2027"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Contineum Therapeutics (CTNM) director Todd R. Brady receive in this Form 4?
Todd R. Brady received a grant of stock options for 19,000 shares of Class A Common Stock. These options were issued under Contineum’s 2024 Equity Incentive Plan as part of its Non-Employee Director Compensation Program after the regular annual stockholder meeting.
What is the exercise price of the Contineum Therapeutics (CTNM) options granted to Todd R. Brady?
The granted stock options have an exercise price of $14.19 per share. This means Brady can purchase up to 19,000 Class A shares at $14.19, regardless of market price, once the options vest and before they expire on June 25, 2036.
When do Todd R. Brady’s Contineum Therapeutics (CTNM) stock options vest?
The options vest in full on the earlier of June 26, 2027 or the next regular annual meeting of stockholders. Vesting is also conditioned on Brady’s continuous service as a non-employee director on the company’s Board of Directors through that vesting date.
How were the 19,000 Contineum Therapeutics (CTNM) options determined for Todd R. Brady?
The 19,000-share option grant is automatic under Contineum’s Non-Employee Director Compensation Program. After each regular annual stockholder meeting, every continuing non-employee director is granted a stock option for 19,000 shares under the company’s 2024 Equity Incentive Plan.
What is the expiration date of the Contineum Therapeutics (CTNM) options granted to Todd R. Brady?
The stock options are scheduled to expire on June 25, 2036. Brady can exercise the options for up to 19,000 Class A shares at $14.19 per share any time after vesting and before this expiration date, subject to plan terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates